Please use this identifier to cite or link to this item: http://repositorio.unifesp.br/handle/11600/30185
Title: Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema - Pilot study of the Pan-American Collaborative Retina Study Group
Authors: Arevalo, J. Fernando
Garcia-Amaris, Rafael A.
Roca, Jose A.
Sanchez, Juan G.
Wu, Lihteh
Berrocal, Maria H.
Maia, Mauricio [UNIFESP]
Pan-American Collaborat Study Grp
Ctr Caracas
Clin Ricardo Palma
Inst Cirugia Ocular
Univ Puerto Rico
Universidade Federal de São Paulo (UNIFESP)
Issue Date: 1-Dec-2007
Publisher: Elsevier B.V.
Citation: Journal of Cataract and Refractive Surgery. New York: Elsevier B.V., v. 33, n. 12, p. 2098-2105, 2007.
Abstract: PURPOSE: To determine the feasibility, safety, and clinical effect of primary intravitreal bevacizumab (Avastin) in patients with cystoid macular edema (CME) after cataract surgery.SETTING: Five institutions in Venezuela, Costa Rica, Puerto Rico, Peru, and Brazil.METHODS: Twenty-eight eyes of 25 patients treated with at least 1 intravitreal injection of 1.25 mg or 2.50 mg of Avastin participated in this interventional retrospective multicenter study at 5 institutions from 5 countries. Baseline and follow-up visits included Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing, optical coherence tomography (OCT) imaging, and ophthalmoscopic examination.RESULTS: the mean follow-up was 32 weeks (range 24 to 52 weeks). Twenty eyes (71.4%) had improved best corrected visual acuity (BCVA) ( >= 2 ETDRS lines), and no eye had worse visual acuity ( >= 2 ETDRS lines). the BCVA remained stable in 8 eyes (28.6%). the mean baseline BCVA was 20/160 (logMAR = 0.92) and the mean final BCVA, 20/63 (logMAR = 0.50); the difference was statistically significant (P <.0001). the mean central macular thickness at baseline (466.3 mu m; range 208 to 784 mu m) decreased significantly (264.5 mu m; range 176 to 513 mu m) by the end of follow-up (P <.0001). Eight eyes (28.6%) required a second injection and 4 (14.3%), a third injection. the mean interval between injections was 13 weeks (range 5 to 26 weeks). No ocular or systemic adverse events were observed.CONCLUSIONS: Short-term results suggest that primary intravitreal Avastin is well tolerated in patients with pseudophakic CME. Treated eyes had a significant improvement in BCVA and decrease in macular thickness by OCT.
URI: http://repositorio.unifesp.br/handle/11600/30185
ISSN: 0886-3350
Other Identifiers: http://dx.doi.org/10.1016/j.jcrs.2007.07.046
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.